Skip to main content
. 2018 Nov 23;85(6):762–772. doi: 10.1093/neuros/nyy449

TABLE 3.

Patient Characteristics and Their Relationship to Different Outcomes Following LA in Univariate Analysis

Factor PFS DSPFS OS DSOS
No (%) or median (range) Median (mo) Pa Sub-hazard ratio (95% C.I) Pb Median (mo) Pa Sub-hazard ratio (95% C.I) Pb
Gender
 Female 10 (42%) 4.7 .59 1.38 (0.56-3.41) .48 24.9 .76 3.10 (0.95-10.2) .06
 Male 14 (58%) 4.2 14.4
Age (yr) 54 (34-75) .61 0.98 (0.95-1.02) .30 .39 1.00 (0.96-1.04) .98
  < 70 18 (75%) 4.3 .63 0.43 (0.13-1.40) .16 21.4 .03 1.31 (0.35-4.96) .69
  ≥ 70 6 (25%) 4.8 8.4
Pre-op KPSc
 60-70 7 (29%) 3.3 .008 0.89 (0.60-1.32) .16 7.4 .15 0.86 (0.44-1.70) .67
 80 8 (33%) 3.5 14.4
 90-100 9 (38%) 9.0 15.2
Tumor location
 Lobar 13 (54%) 4.5 .31 0.79 (0.33-1.92) .61 14.4 .65 0.47 (0.15-1.41) .17
 Othersd 11 (46%) 4.1 22.4
KI 67 (%)e 20% (3-80%) .87 1.01 (0.99-1.02) .31 .42 1.02 (1.00-1.04) .03
  < 20% 5 (28%) 5.7 .08 3.09 (0.74-12.9) .12 15.2 .26 4.05 (0.57-28.8) .16
  ≥ 20% 13 (72%) 4.1 8.5
Tumor volume (cm3) 9.33 (1.3-62.8) .04 1.04 (1.02-1.07) .0006 .61 1.04 (1.01-1.08) .02
  < 11 16 (67%) 5.3 .06 2.26 (0.84-6.08) .11 21.4 .04 3.32 (0.85-12.9) .08
  ≥ 11 8 (33%) 3.6 8.1

PFS: progression-free survival, DSPFS: disease specific progression-free survival, OS: overall survival, DSOS: disease specific overall survival, C.I: confidence interval, KPS: Karnofsky performance status

aLog rank test if 2 categories, Wald test from proportional hazards model if > 2 categories or if the factor is measured on a continuum

bGray's test. The first group listed is the reference; ratios > 1 indicate the risk of death is greater in the second group; ratios < 1 that it is less. For factors measured factors or factors with > 2 categories the hazard ratio represents the change in risk for a 1 unit (category) increment

c3 patients were KPS 60; 1 was KPS 100

dThalamus (n = 7), callosum (n = 2), insula (n = 2)

emissing for 6 patients